Document Detail


Intravascular stents do not cause microangiopathic hemolysis or thrombotic microangiopathy.
MedLine Citation:
PMID:  10540368     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An increased incidence of TTP has been noted among patients receiving intravascular stents to improve patency in diseased coronary, renal, and peripheral arteries. Placement of transjugular intrahepatic porto-systemic shunt stents is often associated with subsequent development of severe hemolysis. We have prospectively studied the development of microangiopathic hemolysis or TTP in patients undergoing intravascular stent placement for peripheral vascular or renal artery disease. Hemolysis was evaluated both before and after stent placement by measuring complete blood count, total bilirubin, lactate dehydrogenase (LDH), haptoglobin and reticulocyte count, and examining peripheral blood films of all patients. Coagulation parameters, blood urea nitrogen and creatinine were measured to exclude disseminated intravascular coagulation or thrombotic thrombocytopenic purpura as a potential cause of hemolysis. Seventeen patients (median age 69 years) were evaluated. One patient was on ticlopidine. Mean hematocrit fell from 41.8% pre-stenting to 35.5% post-stenting (P = 0.003) but without significant change in reticulocyte count (1.7 vs. 1.6%, P = 0.605), LDH (546 vs. 560 IU/l; P = 0.836), bilirubin (0.62 vs. 0.63 mg/dl; P = 1.0), or haptoglobin (183 vs. 158 mg/dl; P = 0.083). Thus, this drop in hematocrit could not be attributed to hemolysis. Peripheral blood films revealed fewer than 1% schistocytes before and after stent placement in all cases. Absence of significant changes in mean platelet count (240 vs. 210 x 10(9)/L; P = 0.088), fibrinogen (385 vs. 378 mg/dl; P = 0.789), BUN (24.5 vs. 16.8; P = 0.079), and creatinine (1.38 vs. 1.24; P = 0.757) argue against development of TTP or DIC resulting from stent placement. No patient developed new renal impairment, a neurological syndrome, or unexplained fever after stent placement. At a mean of 6 weeks follow-up after stent placement, patients have not developed signs of hemolytic anemia or worsening renal function. Our findings argue against a primary risk of microangiopathic hemolytic anemia or TTP due to intravascular stents in patients not receiving ticlopidine.
Authors:
S Mansoor; A Roman; R Weinstein
Related Documents :
17397908 - The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overco...
21550278 - Atlanto-axial subluxation as the initial manifestation of spondyloarthritis.
1509398 - Prevalence of inhibitors in a population of 3435 hemophilia patients in france. french ...
10467278 - Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolon...
7203358 - How often does peptic ulcer produce "typical" ulcer symptoms?
17397908 - The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overco...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of clinical apheresis     Volume:  14     ISSN:  0733-2459     ISO Abbreviation:  J Clin Apher     Publication Date:  1999  
Date Detail:
Created Date:  1999-12-21     Completed Date:  1999-12-21     Revised Date:  2005-07-26    
Medline Journal Info:
Nlm Unique ID:  8216305     Medline TA:  J Clin Apher     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  130-4     Citation Subset:  IM    
Copyright Information:
Copyright 1999 Wiley-Liss, Inc.
Affiliation:
Department of Medicine, St. Elizabeth's Medical Center of Boston Tufts University School of Medicine, Boston, MA 02135, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anemia, Hemolytic / etiology*
Arteries
Humans
Microcirculation / physiology
Middle Aged
Risk Factors
Stents*
Thrombosis / etiology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Experience of double filtration plasmapheresis in the treatment of Guillain-Barré syndrome.
Next Document:  Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma deriva...